Search Clinical Trials
Sponsor Condition of Interest |
---|
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
Varian, a Siemens Healthineers Company
Cervical Cancer by FIGO Stage 2018
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate
that adaptive radiotherapy for locally advanced cervical cancer will translate into a
decreased rate of acute gastrointestinal toxicity compared with the historically reported
rate for non-adaptive intensity modulated... expand
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Type: Interventional Start Date: May 2022 |
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
Brigham and Women's Hospital
Genetic Predisposition to Disease
Hereditary Diseases
This research study is exploring the use of genomic sequencing in the newborn period to
screen healthy babies for current and future health risks. The study will enroll a
diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City,
NY; and Birmingham, AL. A small blood sample... expand
This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City, NY; and Birmingham, AL. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings. Type: Interventional Start Date: Dec 2022 |
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
University of Alabama at Birmingham
Hiv
Alcohol Problem
This study is designed to examine the efficacy of a brief intervention plus a
cognitive-behavioral intervention compared to brief intervention alone to address
unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among
people living with HIV in Alabama. expand
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama. Type: Interventional Start Date: May 2023 |
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
University of Alabama at Birmingham
Sickle Cell Disease
Renal Disease
Glomerular Disease
The investigators will attempt to develop a more accurate equation to estimate eGFR in
pediatric and adult sickle cell patients expand
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients Type: Observational Start Date: May 2021 |
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care
University of Alabama at Birmingham
HIV
AIDS
Smoking Cessation
To determine the efficacy of an algorithm designed to recommend smoking cessation-related
pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS. expand
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS. Type: Interventional Start Date: Aug 2020 |
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and...
University of Alabama at Birmingham
PreDiabetes
One in three American adults have prediabetes, and up to 70% of adults with prediabetes
eventually develop type 2 diabetes. With the high cost of treating diabetes,
cost-effective approaches are needed to reduce the incidence of diabetes. One new
strategy may be to change when people eat. Studies... expand
One in three American adults have prediabetes, and up to 70% of adults with prediabetes eventually develop type 2 diabetes. With the high cost of treating diabetes, cost-effective approaches are needed to reduce the incidence of diabetes. One new strategy may be to change when people eat. Studies in rodents suggest that a form of intermittent fasting that limits eating to a short time period each day and involves fasting for the rest of the day (time-restricted eating; TRE) improves blood sugar control and cardiovascular health. Preliminary studies suggest that TRE also improves blood sugar, weight loss, and cardiovascular health in humans. This study will be the first full-scale, controlled feeding trial to determine whether TRE can improve 24-hour blood sugar control, 24-hour blood pressure, and cardiovascular disease risk factors even when food intake is matched to the control group. This clinical trial will also determine whether the benefits of TRE depend on the time of day that people eat. Participants will be assigned to one of three groups: (1) 'Early TRE' (eat between ~8 am-3 pm), (2) 'Mid-day TRE' (eat between ~1 pm - 8 pm), or (3) Control Schedule (~8 am - 8 pm) for 8 weeks. All food will be provided and matched between groups. Type: Interventional Start Date: Aug 2020 |
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
ProDa BioTech, LLC
Pancreatic Ductal Carcinoma
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the
safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and
nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal
adenocarcinoma (PDAC) expand
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC) Type: Interventional Start Date: Sep 2023 |
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
University of Alabama at Birmingham
Parathyroid Dysfunction
Adenoma
The aim of this study is to determine if fluorescence with or without indocyanine green
can facilitate safe and accurate thyroid and parathyroid surgery. expand
The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery. Type: Interventional Start Date: Apr 2024 |
Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)
University of Alabama at Birmingham
Kidney Diseases
Cardiometabolic Risk Factors
We seek to explore the feasibility and acceptability of participation in a
decision-support training program led by lay navigators. ImPart-Multi, an
education-telehealth-based, is designed to empower Black chronic kidney disease patients
(CKD) patients and their care partner to seek the resources... expand
We seek to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators. ImPart-Multi, an education-telehealth-based, is designed to empower Black chronic kidney disease patients (CKD) patients and their care partner to seek the resources and support needed to be activated allies when making health-related decisions. Participants, based on random assignment, will participate in survey completion at study start and at 12 and 24 weeks of enrollment, and will complete 1, 3, or 4 education sessions via telehealth or audio connection. Participants will also complete an interview to share their thoughts on the program and other factors of interest. Type: Interventional Start Date: Mar 2024 |
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
University of Texas Southwestern Medical Center
Cocaine Use Disorder
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a
combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine
(XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine
use disorder (CUD). expand
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD). Type: Interventional Start Date: Apr 2023 |
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive...
National Cancer Institute (NCI)
Endometrial Serous Adenocarcinoma
Uterine Corpus Carcinosarcoma
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk
(Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the
usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with
HER2 positive endometrial serous carcinoma... expand
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Type: Interventional Start Date: Nov 2022 |
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
HER2-positive Breast Cancer
The purpose of the study is to see if using an investigational drug called [18F]FMISO
with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin)
on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This
study is for imaging purposes only and... expand
The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future. Type: Interventional Start Date: Apr 2025 |
Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
Eyenovia Inc.
Myopia
This study evaluates the progression of myopia in participants using microdosed atropine
0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer
study medication daily in each eye for 48 months. Efficacy and safety assessments will be
performed at visits scheduled for... expand
This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year. Type: Interventional Start Date: Jun 2019 |
Cognitive Training Intervention and Attitudes Towards Genetics
University of Alabama at Birmingham
Cognitive Impairment
Hematologic Neoplasms
Hematopoietic Cell Transplant
A pilot study to evaluate feasibility of enrollment of patients in an intervention to
improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors
using the cognitive training Lumosity program. In addition, patients' interest in
receiving information regarding genetic risk... expand
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured. Type: Interventional Start Date: Aug 2017 |
Retraining and Control Therapy (ReACT) R33 Phase
University of Alabama at Birmingham
Convulsion, Non-Epileptic
The purpose of this study is to assess sense of control and catastrophic symptom
expectations as targets for Retraining and Control Therapy (ReACT- an intervention
focused on changing behaviors and thoughts) for treatment of pediatric psychogenic
non-epileptic seizures (PNES, episodes resembling epileptic... expand
The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of pediatric psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 11-18-year-olds diagnosed with PNES will engage in twelve sessions of either ReACT or supportive therapy. Sense of control over actions will be measured by the magic and turbulence task, a well-validated measure of sense of control. Participants will complete the cold pressor test (CPT) in which participants hold their hand in cool water for as long as possible up to 3 minutes. Catastrophic symptom expectations in response to the CPT will be measured by Pain Catastrophizing Scale for Children (PCS-C), pain tolerance (time with hand in water) and cortisol response. Target assessments occur 7 days before treatment, 7 days after 12th treatment session, and 2 months after the 12th treatment session. Long term follow-up assessments will occur 6 months and 12 months after the 12th treatment session. PNES frequency will be measured from 30 days before to 12 months after treatment. Type: Interventional Start Date: Mar 2024 |
Cold Agglutinin Disease Real World Evidence Registry
Sanofi
Cold Agglutinin Disease (CAD)
Cold Agglutinin Syndrome (CAS)
This is a multinational, multi-center, observational, prospective, longitudinal disease
registry designed to collect data on participants with cold agglutinin disease (CAD) or
cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated
with sutimlimab are expected to take... expand
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry. Type: Observational [Patient Registry] Start Date: Dec 2019 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Malignant Solid Neoplasm
Malignant Female Reproductive System Neoplasm
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors
that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to
other places in the body (advanced)... expand
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors. Type: Interventional Start Date: Apr 2023 |
Functional Outcomes From Diets in Multiple Sclerosis
University of Alabama at Birmingham
Relapsing Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
The purpose of this study is to test the effects of two dietary interventions, glycemic
load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and
anxiety in adults with multiple sclerosis (MS). The investigators will also explore the
how the diet interventions impact... expand
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers. Type: Interventional Start Date: Mar 2023 |
Neurophysiological Mechanisms of Language Comprehension
University of Alabama at Birmingham
Language Disorders
First, in a recording-only self-paced reading experiment, patients with epilepsy
undergoing intracranial monitoring for clinical purposes will read or listen to sentences
presented to them one word at time while the investigators simultaneously record neural
activity through intracranial electrodes... expand
First, in a recording-only self-paced reading experiment, patients with epilepsy undergoing intracranial monitoring for clinical purposes will read or listen to sentences presented to them one word at time while the investigators simultaneously record neural activity through intracranial electrodes that are implanted for clinical purposes (see subject populations). At the end of the sentence, the subjects have to indicate how they comprehended the sentence by selecting which of several pictures matches the sentence they just read. Behavioral measures that the investigators record and analyze are their response times to advance to each next word in the sentence, and which picture they chose for each sentence. These behavioral measures are compared against the neural activity simultaneously recorded as they are made. Then, in a later session, the same participants will participate in a task-related stimulation experiment. This follows the exact same design as the recording-only reading experiment, the only difference is that on some trials, at controlled moments during the sentence presentation intracranial electrical stimulation is delivered through adjacent intracranial electrode contacts. The investigators will examine the effect of this stimulation on the subjects comprehension of the sentences measured by their behavior, and on the simultaneously recorded neural activity. Type: Interventional Start Date: Apr 2022 |
The Arteriovenous Vascular (AV) ACCESS Trial
Wake Forest University Health Sciences
End-Stage Kidney Disease
Hemodialysis Complication
This study is to prospectively compare the effectiveness and safety of the two types of
arteriovenous access placement (fistula or graft) in older adults with end stage kidney
disease and multiple chronic conditions expand
This study is to prospectively compare the effectiveness and safety of the two types of arteriovenous access placement (fistula or graft) in older adults with end stage kidney disease and multiple chronic conditions Type: Interventional Start Date: Aug 2022 |
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
University of Alabama at Birmingham
NF1
Low-grade Glioma
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol
®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The
primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with
progressive low-grade glioma (LGG) as... expand
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below. Type: Interventional Start Date: Dec 2021 |
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment...
National Cancer Institute (NCI)
Bladder Urothelial Carcinoma In Situ
Invasive Bladder Mixed Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating
patients with non-muscle invasive bladder cancer whose cancer does not respond to
Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work
in different ways to stop the growth of... expand
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone. Type: Interventional Start Date: Mar 2020 |
Pulmonary Function Using Non-invasive Forced Oscillometry
University of Alabama at Birmingham
Infant, Premature, Diseases
Infant, Newborn, Diseases
Bronchopulmonary Dysplasia
Respiratory Distress Syndrome, Newborn
Meconium Aspiration Syndrome
The purpose of this observational study is to measure pulmonary function in term and
preterm infants with and without pulmonary disease including respiratory distress
syndrome, bronchopulmonary dysplasia, transient tachypnea of the newborn, meconium
aspiration syndrome, and response to treatments... expand
The purpose of this observational study is to measure pulmonary function in term and preterm infants with and without pulmonary disease including respiratory distress syndrome, bronchopulmonary dysplasia, transient tachypnea of the newborn, meconium aspiration syndrome, and response to treatments given to newborn infants with lung diseases using a non-invasive airway oscillometry system. Type: Interventional Start Date: Dec 2017 |
Longitudinal Study of the Porphyrias
Icahn School of Medicine at Mount Sinai
Acute Porphyrias
Cutaneous Porphyrias
The objective of this protocol is to conduct a longitudinal multidisciplinary
investigation of the human porphyrias including the natural history, morbidity, pregnancy
outcomes, and mortality in people with these disorders. expand
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders. Type: Observational Start Date: Nov 2010 |
Full-Time Occlusion Therapy for Intermittent Exotropia in Children
Jaeb Center for Health Research
Intermittent Exotropia
Determine whether full-time patching is more effective than observation for improving
distance control of IXT after 3 months of treatment (on-treatment outcome). expand
Determine whether full-time patching is more effective than observation for improving distance control of IXT after 3 months of treatment (on-treatment outcome). Type: Interventional Start Date: Nov 2022 |
- Previous
- Next